摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-乙基-9-氧杂麦角灵 | 81244-91-9

中文名称
6-乙基-9-氧杂麦角灵
中文别名
(6aR)-7-乙基-4,6a,7,8,9,10a-六氢-6H-吲哚并[3,4-gh][1,4]苯并噁嗪
英文名称
(-)-trans-4,6,6a,8,9,10a-hexahydro-7-ethyl-7H-indolo<3,4-gh><1,4>benzoxazine
英文别名
trans-4,6,6a,7,9,10a-hexahydro-7-ethyl-7H-indolo<3,4-gh><1,4>benzoxazine;trans-4,6,6a,8,9,10a-Hexahydro-7-ethyl-7H-indolo-[3,4 gh]-[1,4]-benzoxazine;6-Ethyl-9-oxaergoline;(2R,7R)-6-ethyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene
6-乙基-9-氧杂麦角灵化学式
CAS
81244-91-9
化学式
C15H18N2O
mdl
——
分子量
242.321
InChiKey
ILMWHLYQRWFIJV-UKRRQHHQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    28.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    trans-4-(2-chloroacetamido)-1,3,4,5-tetrahydro-1-(p-tolylsulfonyl)benzindol-5-ol 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 sodium hydride 作用下, 以 四氢呋喃乙醇N,N-二甲基甲酰胺 为溶剂, 反应 21.5h, 生成 6-乙基-9-氧杂麦角灵
    参考文献:
    名称:
    (7R)-7H-吲哚并[3,4-gh] [1,4]苯并恶嗪的合成,一种新型的具有多巴胺激动剂活性的D-杂麦角灵。
    摘要:
    介绍了9-氧杂麦角环系统几个成员的合成。制备了4,6,6a,8,9,10a-六氢-7-乙基-7H-吲哚并[3,4-gh] [1,4]苯并恶嗪的C / D顺式和C / D反式异构体,并将C / D反式异构体拆分为其旋光异构体。对[3H]阿扑吗啡结合位点具有最高亲和力的对映体(-)-反式-6-乙基-9-氧杂麦角碱[(-)-6b]具有与天然麦角灵相同的绝对构型,即,6aR,10aR。体内和体外药理学评估表明,这些9-氧杂麦角碱具有有效的多巴胺激动剂特性。
    DOI:
    10.1021/jm00357a010
点击查看最新优质反应信息

文献信息

  • Indolobenzoxazines
    申请人:Merck & Co., Inc.
    公开号:US04238486A1
    公开(公告)日:1980-12-09
    Indolobenzoxazines, their preparation and pharmaceutical use are disclosed.
    本发明揭示了indolobenzoxazines及其制备和药用。
  • Indolobenzoxazines, processes for preparing and pharmaceutical compositions containing the same
    申请人:Merck & Co., Inc.
    公开号:EP0033767A1
    公开(公告)日:1981-08-19
    Novel Indolobenzoxazines of the formula and pharmaceutically acceptable salts thereof wherein (a) R is H, alkyl or aryl, R1 is H, alkyl, aralkyl, cycloalkyl or alkenyl, R2 is H, halogen or alkyl, R3 is H, alkyl or aralkyl, and R4 is H, halogen, alkyl, hydroxy or alkoxy, and their preparation are disclosed. Those novel compounds having antihypertensive protactin inhibiting, and anti-Parkinson activity.
    新颖的式吲哚苯并恶嗪类化合物 及其药学上可接受的盐类,其中 (a) R 是 H、烷基或芳基、 R1 是 H、烷基、芳基、环烷基或烯基、 R2 是 H、卤素或烷基、 R3 是 H、烷基或芳烷基,以及 R4 是 H、卤素、烷基、羟基或烷氧基,并公开了它们的制备方法。这些新型化合物具有抑制高血压原动蛋白和抗帕金森的活性。
  • A new class of D-heteroergolines: total synthesis and resolution of a 9-oxaergoline, 4,6,6a,8,9,10a-hexahydro-7-ethyl-7H-indolo[3,4-gh][1,4]benzoxazine
    作者:Paul S. Anderson、John J. Baldwin、David E. McClure、George F. Lundell、James H. Jones
    DOI:10.1021/jo00132a040
    日期:1982.5
  • US4238486A
    申请人:——
    公开号:US4238486A
    公开(公告)日:1980-12-09
  • Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity
    作者:Paul S. Anderson、John J. Baldwin、David E. McClure、George F. Lundell、James H. Jones、William C. Randall、Gregory E. Martin、Michael Williams、Jordan M. Hirshfield
    DOI:10.1021/jm00357a010
    日期:1983.3
    Synthesis of several members of the 9-oxaergoline ring system is presented. Both the C/D cis and the C/D trans isomers of 4,6,6a,8,9,10a-hexahydro-7-ethyl-7H-indolo[3,4-gh] [1,4]benzoxazine were prepared, and the C/D trans isomer was resolved into its optical isomers. The enantiomer having the highest affinity for the [3H]apomorphine binding site, (-)-trans-6-ethyl-9-oxaergoline [(-)-6b], was shown
    介绍了9-氧杂麦角环系统几个成员的合成。制备了4,6,6a,8,9,10a-六氢-7-乙基-7H-吲哚并[3,4-gh] [1,4]苯并恶嗪的C / D顺式和C / D反式异构体,并将C / D反式异构体拆分为其旋光异构体。对[3H]阿扑吗啡结合位点具有最高亲和力的对映体(-)-反式-6-乙基-9-氧杂麦角碱[(-)-6b]具有与天然麦角灵相同的绝对构型,即,6aR,10aR。体内和体外药理学评估表明,这些9-氧杂麦角碱具有有效的多巴胺激动剂特性。
查看更多

同类化合物

伏高利特 6-乙基-9-氧杂麦角灵 (6aR,10aR)-4,7-二甲基-4,6a,7,8,9,10a-六氢-6H-吲哚并[3,4-gh][1,4]苯并噁嗪乙二酸酯 Trans-7-[2-(4-benzylpiperazin-1-yl)-1-oxoethyl]-4,6,6a,8,9,10a-hexahydro-10a-methyl-4-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-7-chloroacetyl-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine trans-4,6,6a,7,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-indolo[3,4-gh][1.4]benzoxazin-8-one trans-4,6,6a,8,9,10a-hexahydro-10a-methyl-1-(2,4,6-triisopropylphenylsulfonyl)-7H-indolo[3,4-gh][1.4]benzoxazine 4,6,6a,8,9,10a-hexahydro-10a-methylindolo[3,4-gh][1.4]benzoxazine 4,6a,7,8,9,10a-Hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) 7H-Indolo(3,4-gh)(1,4)benzoxazine, 4,5,5a,6,6a,8,9,10a-octahydro-7-propyl-, (+-)-, (5a-RS(5a-alpha,6a-beta,10a-alpha))- Oxalic acid--5-bromo-7-methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine (1/1) 7-Propyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) Paspaclavin 7-Methyl-4,6a,7,8,9,10a-hexahydro-6H-indolo[3,4-gh][1,4]benzoxazine--hydrogen chloride (1/1) trans-4,6,6a,8,9,10a-hexahydro-7-n-butyl-7H-indolo-[3,4 gh]-[1,4]-benzoxazine trans-4,6,6a,8,9,10a-Hexahydro-7H-indolo-[3,4-gh]-[1,4]-benzoxazine 9-Oxaergoline, 2-bromo-6-propyl-, monohydrochloride, (+-)- 4,6,6a,8,9,10a-Hexahydro-10a-methyl-7-(2-phenoxyethyl)-7H-indolo[3,4-gh][1.4]benzoxazine (6aRS,10aRS)-4,6,6a,8,9,10a-hexahydro-7H-indolo<3,4-gh><1,4>benzoxazine 6-Methyl-4-(methylsulfanylmethyl)-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2S,7S)-6-ethyl-15-methoxy-2-methyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraene 10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene;hydron;chloride (2R,7R)-6,11-dimethyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene (2R,7R)-10-bromo-6-propyl-3-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene 5,6-Dimethyl-3-prop-1-en-2-yl-4-oxa-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene